A randomized controlled trial for the Liger thermal coagulator for the treatment of pre-invasive disease of the uterine cervix: Chinese Multi-Center Cervical Cancer Screening Trial (CHIMUST)

Chinese Multi-Center Cervical Cancer Screening Trial (CHIMUST) Phase III study of the Liger thermal coagulator for the treatment of pre-invasive disease of the uterine cervix

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031895

Enrollment

Unknown

Registered

2020-04-13

Start date

2017-05-10

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical lesion

Interventions

Thermocoagulation group:Thermocoagulation

Control group:Cryotherapy

Eligibility

Sex/Gender

Female

Age

30 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Women between the ages of 30-59 who met eligibility criteria and therefore participated in the Chinese Multi-Site Screening Trial (CHIMUST, in Inner Mongolia and Jiangxi Provinces), and whom because of positive screening tests underwent colposcopic examination and were determined by cervical biopsy to have CIN2 and or CIN3; 2. Women who consent to being randomized to treatment with one of the two study devices

Exclusion criteria

Exclusion criteria: Any woman not meeting the two criteria listed in eligibility.

Design outcomes

Primary

Measure	Time frame
pathology;cytology;HPV;	—

Countries

China

Contacts

Public ContactRuifang Wu

Peking University Shenzhen Hospital

wurf100@126.com+86 13827433039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026